Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma
By
- AMS
posted
Jun 14, 2021 01:48 PM
0
Recommend
.
0 comments
0 views
Permalink
Related Content
Researchers Analyze How Breast Implant Surfaces Influence Immune Response
- AMS
Added Jul 13, 2021
Blog Entry
Limb melanomas: acral melanomas have worse survival
- AMS
Added Feb 16, 2021
Blog Entry
COVID-19 in 3 patients treated with immune checkpoint inhibitors for advanced melanoma
- AMS
Added Oct 23, 2020
Blog Entry
Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses
- AMS
Added Mar 23, 2021
Blog Entry
Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events
- AMS
Added Apr 22, 2020
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic